Avalo Therapeutics’ AVTX-009 is advancing in hidradenitis suppurativa, with Phase 2 data expected in 2026. Stifel initiates coverage with a $36 price target.
Latest Ratings for AVTX
DateFirmActionFromTo Mar 2022JefferiesDowngradesBuyHold Mar 2022RBC CapitalMaintainsOutperform Sep 2021RBC CapitalInitiates Coverage OnOutperform